Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Eli Lilly's Mounjaro diabetes and weight-loss drug approved in India in KwikPen device, offering personalized treatment ...

Eli Lilly's experimental obesity therapy bimagrumab drew mixed reactions from Wall Street after the company recently ...

India’s drug regulator has given the nod to Eli Lilly’s once-a- week Mounjaro (tirzepatide) injection in the KwikPen format, ...

Eli Lilly poised for 30-50% growth in 12 months with a strong value and growth nexus. Click here to read more on LLY stock.

Citi reaffirmed its bullish view on Eli Lilly (NYSE:LLY) stock as it sees significant upside from orforglipron, the company’s once-daily oral obesity drug candidate.

An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the ...

Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...

Each Mounjaro KwikPen delivers four fixed doses of 0.6 mL and will available in the Indian market in six dose strengths of  2 ...

Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...

Some doctors are concerned that patients taking weight loss drugs like Wegovy may be losing too much lean mass. A combination ...

Eli Lilly said the response for its blockbuster drug Mounjaro has been "positive" in India, adding that it is focusing on ...